ClinicalTrials.gov record
Completed Phase 1 Interventional

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

ClinicalTrials.gov ID: NCT01026415

Public ClinicalTrials.gov record NCT01026415. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 15, 2026, 4:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) in Patients With CD30-Positive Hematologic Malignancies: CYP3A4 Drug-Drug Interactions, Excretion, and Special Populations

Study identification

NCT ID
NCT01026415
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Seagen Inc.
Industry
Enrollment
73 participants

Conditions and interventions

Interventions

  • brentuximab vedotin Drug
  • ketoconazole Drug
  • midazolam Drug
  • rifampin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2009
Primary completion
Apr 30, 2012
Completion
Apr 30, 2012
Last update posted
Dec 17, 2014

2009 – 2012

United States locations

U.S. sites
6
U.S. states
6
U.S. cities
6
Facility City State ZIP Site status
City of Hope Duarte California 91010
Colorado Blood Cancer Institute Denver Colorado 80218
St. Francis Medical Group Oncology & Hematology Specialists Indianapolis Indiana 46237
Karmanos Cancer Institute / Wayne State University Detroit Michigan 48209
Hackensack University Medical Center Hackensack New Jersey 07601
Seattle Cancer Care Alliance / University of Washington Medical Center Seattle Washington 98109-1023

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01026415, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 17, 2014 · Synced May 15, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01026415 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →